EXTRACTS OF THE ACANTHOSPERMUM HISPIDUM PLANT

Abstract: The invention relates to an aqueous extract of the Acanthospermum hispidum plant and its use as a medicament. The extract is effective as an immunomodulator, in the remedy of radiation sickness, in the prophylaxis and therapy of virus diseases and in the prophylaxis and therapy of retroviral diseases in mammals, and has an antitumor effect.

Description: Extracts of the Acanthospermum hispidum plant The invention relates to an extract of the Acanthospermum hispidum plant containing water-soluble components with a molecular weight > 2,000. The invention also relates to the use of the Acanthospermum hispidum extract as a medicament. Furthermore, the invention relates to the use of extracts of the Acanthospermum hispi¬ dum plant for the immunomodulation (influencing the immune state) of mammals, for the remedy of radiation sickness as well as for the prophylaxis and therapy of viral and retro- viral diseases in mammals and for the therapy of tumors. Finally, the invention relates to a method for producing an extract of parts of the Acanthospermum hispidum plant and effecting separation of the ingredients based on their mo¬ lecular weight. Acanthospermum hispidum (compositae) is a plant originating from South America which has spread worldwide throughout the Tropics. In traditional medicine West African primitive tribes have used Acanthospermum hispidum (A.h.) for the pro¬ duction of tea (extracts) useful in the treatment of jaun¬ dice. Furthermore, A.h. is used in the treatment of Herpes labialis, the juice of the leaves being swabbed on the af¬ fected area. The therapeutic effect of said extracts (as well as that of the leaf juice) in the treatment of Herpes labialis is the following: pain relief within one to three hours after ap¬ plication, reduction of the healing process to two to three days and extension, of the relapse intervals. If this natural remedy is applied within the first few hours after the symp¬ toms have begun to appear, it will usually completely sup¬ press any lesion formation. The extract is also effective against Herpes genitalis. A list of the ingredients of A.h. can be taken from the monograph "The Biology and Chemistry of the Compositae", V.H. Heywood, J.B. Harborne and B.L. Turner (eds.). Academic Press, London, New York, San Francisco, 1977. Melampolides, galactosides, acetylenes were isolated from A.h. by the F. Bohlmann group in Berlin, and their chemical structure was clarified. (Phytochemistry, 1979, Vol. 18, pages 625-630; Planta Medica, 1986, pages 154-155; Phytochemistry, 1976, Vol. 15, pages 1776-1778). The essential oils of said plant were studied to find out their microbial and antifungal effect (S.R. Jain et al., Planta Medica, 1972, Vol. 22, page 136; and S.R. Jain and A. Kar, Planta Medica, 1971, Vol. 20, page 118) . Toxicological studies on the use of A.h. as a fodder plant were conducted by B. Ali and I. Adam in goat and mice (J. Comp. Pathology, 1978, Vol. 88, pages 443-448 and pages 533-544) . However, Acanthospermum hispidum or an extract of said plant has not been used widely so far, as it has not been possible to administer it orally due to the toxicity of some of its ingredients. Thus, the object underlying the invention is to provide a non-toxic but therapeutically active Acanthospermum hispidum preparation. This object is achieved by the surprising find¬ ing that the removal of low molecular components from the Acanthospermum hispidum extract causes the toxic effect of the extract to disappear. Thus, one subject matter of the invention is the provision of an extract of the Acanthospermum hispidum plant contain¬ ing the water-soluble components thereof with a molecular weight > 2,000. A further subject matter of the invention is the provision of the mentioned extract of the Acanthospermum hispidum plant for use as a medicament, especially as an immunomodu- lator, in the remedy of radiation sickness, in the prophy¬ laxis and therapy of viral diseases or retroviral diseases in mammals and in the therapy of tumors. It is preferred that the extracts of the invention be aqueous Acanthospermum hispidum extracts. However, there have also been used other extracting agents such as ethanol, chloroform, isopropanol, gasoline, and the like. The inven¬ tion will be discussed hereinafter and exemplified by an aqueous extract. The term "aqueous extract" shall be under¬ stood to mean a substantially aqueous extract, i.e., it may contain small amounts of a non-aqueous solvent, e.g., not more than 10, preferably not more than 5% by volume, or a water-soluble compound, e.g., salts, sugar such as glucose, or acids such as ascorbic acid, as long as the substantially aqueous character of the extract is not affected. To obtain the extract, fresh or dried Acanthospermum hispi¬ dum leaves are suspended in water, which may, if desired, contain any of the aforementioned additives, and homogenized at a temperature between 4 β C and 100 β C, preferably at room temperature. The insoluble components are first separated by way of centrifugation and filtration. The supernatant and the filtrate, respectively, are freeze-dried so as to remove the volatile substances from the extract. The product is then dissolved in destilled water, centri- fuged to remove their insoluble components and subjected to a treatment for removing the components with a low molecular weight. It is preferred that centrifugation is effected at 100,000g for an hour and dialysis is done against phosphate- buffered physiological salt solution (PBS) . In another em¬ bodiment the low molecular components are separated out by way of ammonium sulfate precipitation. These steps ensure that components with a molecular weight < 2,000 be removed from the extract. The below-described biological activities are contained in the macromolecular fraction. The enzymatic treatment of the extract with trypsin, chymo- trypsin, pronase, amyloglucosidase or DNAase does not change the activity thereof. Nor is its activity destroyed by heat (5 minutes, 100 β C), but what does destroy it is acidic hy¬ drolysis or periodate oxidation. The portion of amino acids is very small, aibout 0.2%. The following sugars are con¬ tained in the extract: rhamnose, fucose, ribose, arabinose, xylose, mannose, glucose, and galactose. The aqueous extract of the invention (hereinafter referred to as "A.h. extract") exhibits a number of biological activities: 1. Direct antiviral and antiretroviral activity: It was shown in VST (vesicular stomatitis virus) , in MHV3 (mouse hepatitms virus 3), and in HIV (human immune defi¬ ciency virus) . VSV and HIV were incubated with A.h. extract and then titered with mouse fibroblast cell cultures (VSV) and MT4 cells (HIV) , respectively, to measure the virus neutral¬ izing effect of A.h. extract. The results of these assays demonstrate that a lasting virus neutralization is achieved even with highly diluted A.h. extracts. The potential use of A.h. extract in the therapy of infected individuals was tested in mice which had been infected with MHV3 and administered either sub- cutaneously or orally different doses of A.h. extract. Compared to control mice which had been likewise in¬ fected, but given no A.h. extract, a considerably in¬ creased survival rate was observed after administration of A.h. extract over a period of five days. 2. Positive influence on the immune state of mammals: It was shown in human and mouse cell cultures by admin¬ istration of A.h. extract. In addition to the virus neutralizing effect a positive influence on the immune state was observed. Also, assays were carried out in different systems. To see whether or not it was possible to induce the pro¬ liferation of B-lymphozytes, mouse spleen cells (CBF) were incubated with different A.h. amounts. The prolif¬ eration of the spleen cells was determined with 3 H-thym- idine or with alkaline phosphatase. In the supernatants of the spleen cell cultures after 5 days the IgM concentration was measured, thus determining the stimulation of IgM synthesis in mouse spleen cell cultures. In further assays mouse bone marrow macrophages (KMM) were used to measure the stimulation of oxygen rad¬ ical production and the induction of the proliferation of adult bone marrow macrophages. Analogous assays were made to stimulate oxygen radical production in human granulo- zytes and to induce the proliferation of peripheral human lymphocytes. In all these cases a clearly stimulating and inducing effect of A.h. extract on the cell cultures was observed. It was possible to detect induction of interferon forma¬ tion in mouse bone marrow macrophages. For that purpose bone marrow macrophages were incubated with different di¬ lutions of A.h. extract for one hour and the cells, after washing, further cultivated without A.h. extract for an additional 24 hours. Interferon was detected in the su- pernatants of these cultures by neutralization of viruses. The system was stomatitis mouse virus. 3. Therapy of radiation sickness: It was done in mouse bone marrow macrophages which had been radiated with a soft X-ray source. The clearly in¬ creased survival rate of cells treated with A.h. extract as over non-treated cells was determined by reduction of a dye. 4. Tumor-therapeutic activity: It was shown in the effect on the mouse Meth A- fibrosarcoma. Since the assays on the effect of A.h. extract revealed that both specific and unspecific defense mechanisms of the organism were stimulated, it surprisingly turned out that A.h. extracts possess a very strong antitumor effect which has been successfully tested in vivo in tumor- therapeutic models. The test model was a methyl cholan- threne induced transplantable mouse fibrosarcoma (Meth A- fibrosarcoma, induced by L. Old at the Sloan Kettering Institute for Cancer Research in New York, U.S.A.). For that purpose a defined small amount of tumor cells is injected intracutaneously into the central abdomen of in¬ bred mice which are genetically compatible with the fib¬ rosarcoma. This tumor shows uniform, relatively rapid growth in all mice and results, without therapy, in the death of the animals within five weeks. It is easy to de¬ termine the size of the tumor, as it grows directly under the skin, thus being readily measureable from the outside. In the assay CBFl mice were injected intracutaneously with Meth A-fibrosarcoma cells into the shaved central abdomen. At days 3, 5 and 7 following implantation of the tumor, A.h. extracts were injected subcutaneously into the vicinity of the inginal lymph nodes. At days 7, 14, 21 and 28 after insertion of the tumors, their diameters were measured, and the tumor mass calculated. At the end of the assay, the number of cured animals was determined. The therapy with A.h. extract first delays tumor growth, then shrinks the tumor mass and eventually results in tumor shedding in the majority of the animals. The ex¬ tracts led to a regression rate of up to 100%, i.e., all the animals treated were cured. Long-term observation lasting several months revealed no relapse in the cured mice. Of particular interest is the fact that the tumor shed¬ ding takes place at a time when therapy is already accom¬ plished. This indicates that A.h. extract displays a long-lasting therapeutic effect. The enclosed drawings show: Fig. 1: the antiviral activity of A.h. extract against mouse VSV exemplified by L929 fibroblasts. Each dot shows the titer of the individual cultures with and without A.h. extract. Fig. 2: the antiretroviral activity of A.h. extract against HIV, measured in MT4 cells. HI viruses are neutral¬ ized by A.h. extract until a dilution of 1:400 is obtained. Fig. 3: the induction of the proliferation of B-lymphozytes of mouse CBF spleen cells. Proliferation is de¬ termined with 3 H-thymidine or alkaline phosphatase. Fig. 4: the stimulation of mouse bone marrow macrophages. Determination is effected by conversion of short¬ lived oxygen radicals into light pulses. The oxygen radicals are received by lucigenin or luminol. Fig. 5: the induction of the proliferation of adult mouse bone marrow macrophages, measured by 3 H-thymidine insertion. Fig. 6: the therapy of radiation sickness in mouse bone marrow macrophages. The viability test is done by photometric measurement (570 nm) of the reduction of MTT (3-(4,5-dimethyl-thiazole-2-yl)-3,5-di- phenyltetrazolium bromide) . Bone marrow macrophages are radiated -at different doses using a soft X-ray source (60KV, 25 mA) . One hour after radiation, A.h. extract is added. After different cultivation times of the cultures with A.h. extract and con¬ trols without A.h. extract, the cells are mixed with lOμl of MTT solution (5 mg/ml) and the extinc¬ tion data determined. Fig. 7: the tumor-therapeutic activity of A.h. extract against mouse Meth A-fibrosarcoma. The mass of in¬ duced tumors is determined at days 7, 14, 21 and 28 after insertion of the tumor and injection of A.h. extract. The right-hand column indicates the number of cured animals and the total of assayed animals. Fig. 8: the stimulation of oxygen radical production in human granulozytes. Measurement is analogous to the method indicated in Fig. 4. Fig. 9: the induction of the proliferation of peripheral human lymphozytes after administration of A.h. ex- tract. The insertion of * _H-thymidme was measured. The examples illustrate the invention. E x a m p l e 1 Production of Acanthospermum hispidum extract from fresh leaves. a. One kg of freshly picked Acanthospermum hispidum leaves are washed twice with 5 liters of distilled water. The drained leaves are mixed with 1 liter of distilled water, poured into a homogenizer (e.g.. Warring Blendor) and homogenized until the leaf parts are smaller than 1 mm 2 . The temperature prevalent in the preparation during this process should not be in excess of 30 β C. The leaf pulp is centrifuged at 6,000g for 20 minutes. The supernatant is filtrated through a Whatman filter No. 1 and freeze-dried. The yield is about 30 g. This crude extract can be stored in a dry place at 4'C until further use. b. Six g of crude extract are mixed with 300 ml of distilled water, resulting in a turbid solution. The mixture is ul- tracentrifuged at 100,000g for one hour at 4 β C. Then the supernatant is dialyzed against 4 x 10 1 of distilled water for 12 hours at 4°C. The dialyzed extract is either deep-frozen at -20"C or freeze-dried. The yield is about 1.2 g. c. For ammonium sulfate precipitation, 13.24 g of ammonium sulfate (final concentration 1 M) are slowly added to 100 ml of dialyzed extract at 0°C with constant stirring. By using a 25% ammonia solution, the pH is adjusted to 7.2. At 0°C, stirring is continued for an additional 30 minutes and so is precipitation. Then the mixture is centrifuged at 3,O00g for 10 minutes (4 β C). The supernat¬ ant (1 M) is stored and the sediment resuspended in 10 ml of 1 M ammonium sulfate solution for washing. The mixture is again centrifuged at 3,000g for 10 minutes (4 β C) and the supernatant from washing discarded. Sediment 1 M is dissolved in 30 ml of distilled water. To supernatant 1 M there are slowly added 13.24 g of ammonium sulfate (final concentration 2 M) at 0*C with constant stirring. By using a 25% ammonia solution, the pH is adjusted to 7.2 and precipitation continued at O'C for 30 minutes. The mixture is centrifuged at 3,000g for 10 minutes (4 d C). Supernatant 2 M is stored. Sediment 2 M is resuspended in 5 ml of 2 M ammonium sulfate solution and again centri¬ fuged at 3,000g for 10 minutes (4°C). The supernatant from washing is discarded. Sediment 2 M is dissolved in 20 ml of distilled water. Sediment l M, sediment 2 M, and supernatant 2 M are each dialyzed against 10 1 of distilled water 4 x 12 hours at 0*C, and the dialysates are freeze-dried. The yield is: sediment 1 M about 200 g; sediment 2 M about 50 mg; su¬ pernatant 2 M about 95 mg. E x a m p l e 2 Production of Acanthospermum hispidum extract from dried leaves. 200 g of air-dried leaves are crushed by means of a cutting mill. For swelling, the crushed leaves are mixed with 1 1 of distilled water and stirred at 4'C for 18 hours. The mixture is homogenized in a homogenizer (e.g. , Warring Blendor) 3 x 60 seconds. The mixture is heated to 100°C in a water bath for 10 minutes. Then it is centrifuged and freeze-dried as in Example 1. Further processing takes place as in Example 1, items b and c. The yield in crude extract is about 3.5 g, in dialyzed extract about 0.75 g, in sediment 1 M about 5 mg, in sediment 2 M about 55 mg, and in supernatant 2 M about 85 mg. E x a m p l e 3 Proliferation of mouse spleen cells in the presence of A.h. extracts. Spleen cells are removed from inbred mice (e.g., CBFl, C3H, Balb/c) under sterile conditions. A cell suspension is pre¬ pared by means of a loose potter homogenizer. Following centrifugation (5 minutes, 700g, 4 β C), the spleen cells are resuspended in tissue culture medium (DMEM) . The medium con¬ tains the following additives: 10% fetal calf serum, 50 μM 2-mercaptoethanol, 5 μg of streptomycin/ml and 100 I.E. penicillin/ml. The cells are adjusted to a concentration of 5,000,000/ml. 0.2 ml of cell suspension is poured into each hole of micro- titer plates (of the flat bottom type) . Then 10 μl of the various A.h. extract solutions (sterilized by filtration) , respectively, are added. The microtiter plates comprising the cell cultures are incubated in a gassed incubator (37"C, 10% C0 2 , 98% RH) for different periods of time according to the assay preparation. Parallel cultures are prepared so as to measure B-cell proliferation at different days. This is necessary because the cultures will be destroyed as a result of the harvest procedure after 3 H-thymidine is added. To measure cell proliferation, the microtiter plates are cent¬ rifuged at 700g for 10 minutes at room temperature. The cell sediments are mixed with 200 μl of new culture medium (plus the additives as above) and of 0.2 μCi 3 H-thymidine, respectivel . After 6 hours of further incubation in a gassed incubator, the cells are harvested with a commercial harvester (e.g., Skatron cell harvester) . Radioactivity in the cellular DNA is determined with a commercial 3-scintillation counter. Table I shows the results of an experiment of Example 3. The cells were incubated for four days prior to measuring pro¬ liferation. Proliferation is indicated in % with respect to the control. The figure in parentheses indicates the 3 H- pulses per minute in the control. 10 μg of A.h. extract were added to each culture. Table I Extracts: control dialyzed 1 M 2 M % 100 (5,730) 370 528 237 E x a m p l e 4 Stimulation of IgM synthesis in spleen cell cultures by A.h. extracts. Immunoglobulines of class M (IgM) are measured, as it is this antibody class which is primarily synthesized in vitro. The cultures are prepared on microtiter plates as in Example 3. After five days of incubation (37'C, 10% C0 2 , 98% RH) , centrifugation takes place at 700g for five minutes at room temperature. 100 μl of each supernatant are removed and put on a new microtiter plate which has been pre-treated for the ELISA mouse IgM assay. The indicator reagent is an antimouse IgG (goat) antiserum which has been coupled with alkaline phos- phatase. The antibody amounts are apparent from Table II and indicated in μg/ml. Table II A.h. (μg) - < 5 2.5 1.25 0.625 (dialyzed) IgM (μg/ml) 2.4 17.0 12.5 7.8 5.3 E x a m p l e 5 Proliferation of mouse macrophages by A.h. extracts. The macrophages are grown in vitro according to the Metcalf method. For this purpose bone marrow cells from a mouse femor are isolated and cultivated in a culture medium (DMEM) containing 30% of fibroblast culture supernatant from cell line L929 and 5% of horse serum. These additives cause the parent cells to proliferate and differentiate exclusively in macrophages. After 10 days of incubation, these cultures only consist of pure macrophages which show no proliferation any more. By the addition of A.h. extracts, they surprising¬ ly start anew to divide without dedifferentiating taking place. Said proliferation is measured as follows: 20,000 macrophages are mixed with 200 μl of culture medium (as in Example 3) and poured into each hole of microtiter plates. Thereto are added 10 μl of the various A.h. ex¬ tracts, respectively. In a gassed incubator the mixture is incubated for four days and then centrifuged at room temperature (700g/5 minutes) . If desired, the supernatants are stored for interferon determination. 200 μl of culture medium and of 0.2 μCi 3 H-thymidine, respectively, are pipetted onto the cells. Then incubation is continued in the gassed incubator for an additional 24 hours. The microtiter plates comprising the cultures are frozen at -20"C to remove the macrophages adhering to the culture flask and thawed, and the radioactivity of the cellular DNA is determined as in Example 3. E x a m p l e 6 Determination of interferon induction by A.h. extracts in the mouse bone marrow macrophage culture. 100,000 macrophages are mixed with 200 μl of culture medium (DMEM; as in Example 3) and poured into each hole of micro¬ titer plates. Using different A.h. dilutions, the mixture is incubated for one hour. The cells are washed once in culture medium and cultivated for an additional 24 hours in the absence of A.h. extract. Then the supernatants are removed by means of a pipette for interferon determination. Interferon determination is based on the neutralization of the virus of the vesicular stomatitis of the mouse. Said virus is capable of infecting mouse fibroblasts (cell line L929) and destroying them by virus proliferation and secre¬ tion. Said cytopathological effect can be observed microscopically. For that purpose 20,000 L929 cells are sown in 100 μl of culture medium on microtiter plates. 100 μl of the macrophage culture supernatants or, as con¬ trols, A.h. extracts (diluted in 100 μl of medium) are added. The microtiter plates are incubated in a gassed incubator for 24 hours (37 * C, 10% C0 2 , 98% RH) . 10 μl (corresponding to 7,000 infectious units) of vesicular stomatitis virus (VSV) are added in each hole. Then incubation is continued in the gassed incubator for an additional 48 hours. Cell destruction (cytopathic effect) or possible inhibition by interferon in the culture is read microscopically. Table III shows the results of such an experiment. The neg¬ ative signs indicate cell destruction (cytopathic effect) , the positive its ^inhibition by the presence of interferon. 0 . 5 Stimulation of oxygen radical production in mouse bone mar¬ row macrophages. Macrophages from the bone marrow are grown in teflon bags according to the Metcalf method (see Example 5) . Measurement is taken by conversion of the very short-lived oxygen rad¬ icals into light pulses. For this purpose substances such as lucigenin or luminol which serve as receptors for oxygen radicals are used. As a result of oxidation processes, photons are formed which are measured by commercial appar¬ atuses (Biolumat manufactured by Berthold) . The assay pre¬ paration is made as follows: 200,000 bone marrow macrophages are incubated in 0.2 ml of DMEM without phenol red and NaHC0 3 with 50 mM Hepes as a buffer at 37 β C for one hour. Measurement is taken after ad¬ ding 0.2 ml of DMEM, 10 μl of lucigenin solution (11.6 μmole) , and 10 μl of the corresponding A.h. dilution (1 mg/ml) . E x a m p l e 8 Therapy of radiation sickness in mouse bone marrow macrophages. Mouse bone marrow macrophages are radiated with a soft X-ray source (60 KV, 25 mA) . The viability of the cells is deter¬ mined by means of reduction of MTT (3-(4,5-dimethylthiazole- 2-yl)-3,5-diphenyltetrazolium bromide). 100,000 KMM are in¬ cubated in each hole. The A.h. extract is added one hour after radiation. After different cultivation times, the cells are mixed with 10 μl of MTT solution (5 mg/ml) , the plates are centrifuged after 4 hours of incubation at 37"C, the culture medium is removed and the tetrazolium blue crystals are dissolved in 100 μl of isopropanol - 0.04 M HC1. The color is read in_a microtiter photometer at 570 nm. E x a m p l e 9 Tumor-therapeutic activity on the mouse Meth A-fibrosarcoma. CBFl mice are each injected intracutaneously with 50,000 Meth A-fibrosarcoma cells in the shaved central abdomen. At days 3, 5, and 7 following tumor implantation, 1 mg of A.h. extract is injected subcutaneously into the vicinity the inginal lymph nodes. At days 7, 14, 21, and 28 after insertion of the tumors, their diameters are determined. As tumors do not grow in a totally round shape, the smallest and largest diameter is measured using a slide gauge. The tumor mass is calculated according to the formula a+b v ~ 6 which corresponds to the volume of half an ellipsoid. E x a m p l e 1 0 Induction of the- proliferation of peripheral human blood ly phozytes (PBL) by A.h. extracts. 20 ml of heparinised whole blood (5 I.E. heparin/ml) are di¬ luted with 60 ml of physiological salt solution. 5 ml of Ficoll Isopaque solution (density 1.17) are poured into centrifuge tubes and covered with 5 ml of the diluted blood. Centrifugation takes place at l,700g for 30 minutes at 23°C. The cells which are found between the lower (Ficoll Isopaque) and the upper (diluted plasma) phase are removed by means of a pipette. The cells are then diluted with the 10-fold volume of physiological salt solution. The mixture is centrifuged at 700g for 10 minutes at room temperature and the supernatant discarded. The cell sediment is resuspended twice in 10 ml of physiolo¬ gical salt solution and centrifuged as above. The cell sedi¬ ment is mixed with DMEM + fetal calf serum + additives (see Example 3) and adjusted to a concentration of 500,000 cells/ml. Each hole of microtiter plates (of the flat bottom type) is filled with 0.2 ml of cell suspension (100,000 PBL each hole) . In the holes there are added 10, 5, 2.5, 0 μg of the A.h. extract solutions. The microtiter plates comprising the cell cultures are incubated in a gassed incubator (37"C, 10% CO,, 98% RH) for four days. The cultures are centrifuged at 700g for 10 minutes at room temperature and the supernatants discarded. The cell sediments are mixed with 200 μl of culture medium + additives + 0.2 μCi 3 H-thymidine, respectively. After 24 hours of further incubation in the gassed incuba¬ tor, the cells are harvested, and the radioactivity in the cellular DNA is determined as indicated in Example 3. E x a m p l e 1 1 Direct antiviral activity against vesicular stomatitis virus (VSV) . 0.5 ml of VSV with a titer of 2 x 10 infectious particles/ml are incubated with 2.5 μg of A.h. extract in Hepes buffered DMEM at 23°C for one hour. This preparation and the corres¬ ponding control without A.h. extract are diluted with DMEM in logarithms (1:2, 1:4, 1:8, 1:16, etc.). 10 μl of the respective dilution are added to the cultures of L929 fibroblasts on microtiter plates (5 x 10 4 cells/hole) . After 48 hours of incubation at 37 β C, 10% C0 2 . and 98% humidity, the cytopathic effect is read. Fig. 1 shows the lowest dilutions which are negative. E x a m p l e 1 2 Direct antiviral activity against MHV3. 0.5 ml of MHV3 virus suspension with a titer of 2.5 x 10 3 infectious particles/ml are incubated with various amounts of A.h. extract according to Table IV in Hepes buffered DMEM at 23 β C for one hour. 10 μl of the respective preparation are added to L929 "cultures on microtiter plates and incu¬ bated for 24 hours (number of cells: 5 x 10 4 /h°l e , incuba¬ tion conditionss 37"C, 10% C0 2 , 98% humidity). The resultant plaques are determined microscopically from eight parallel cultures. Table IV A.h. (μg/culture) 0 0.035 0.07 0.15 0.3 0.6 1.25 2.5 plaques/ culture 25 10.5 3.5 1.3 0.3 0.2 0 0 E x a m p l e 1 3 Direct antiretroviral activity against HIV. Cells of the T cell line MT4 are infected with HIV-1 (titer dilution 1:200) with or without an A.h. extract dilution (10 μl/hole) on a microtiter plate. The dilution of A.h. extract up to which HIV-1 is neutral¬ ized is determined.

Claims: P a t e n t C l a i m s 1. An extract of the Acanthospermum hispidum plant contain¬ ing the soluble components thereof with a molecular weight > 2,000. 2. An extract of the Acanthospermum hispidum plant contain¬ ing the soluble components thereof with a molecular weight > 2,000 for use as a medicament. 3. The extract of claim 2 for use as an immunomodulator. 4. The extract of claim 2 for use as an antitumor agent. 5. The extract of claim 2 for use in the remedy of radia¬ tion sickness. 6. The extract of claim 2 for use in the prophylaxis and therapy of virus diseases in mammals. 7. The extract of claim 2 for use in the prophylaxis and therapy of retrovirus diseases in mammals. 8. Use of extracts of the Acanthospermum hispidum plant as an immunomodulator. 9. Use of extracts of the Acanthospermum hispidum plant as an antitumor agent. 10. Use of extracts of the Acanthospermum hispidum plant for the remedy of radiation sickness. 11. Use of extracts of the Acanthospermum hispidum plant in the prophylaxis and therapy of virus diseases in mammals. 12. Use of extracts of the Acanthospermum hispidum plant in the prophylaxis and therapy of retrovirus diseases in mammals. 13. A method for , the production of the extract of claim 1 characterized by extracting parts of the Acanthospermum hispidum plant with water and then separating the ingre¬ dients with a molecular weight < 2,000 from the extract. 14. The method of claim 11 characterized by using green leaves of the plant for extraction. 15. The method of claim 11 characterized by using dried leaves of the plant for extraction. 16. The method of claim 11 characterized by carrying out said extraction at a temperature between 4"C and 100°C. 17. The method of claim 11 characterized by effecting said separation of the components with a molecular weight < 2,000 from the extract by way of dialysis. 18. The method of claim 11 characterized by effecting said separation of the components with a molecular weight < 2,000 from the extract by way of ammonium sulfate precipitation. 19. A method for stimulating immunomodulation characterized by administering to a patient in need of such treatment an immunomodtilatory amount of extract of the Acantho¬ spermum hispidum plant of claim 1. 20. A method for stimulating an antitumor response charac¬ terized by administering to a patient in need of such treatment an antitumor amount of extract of the Acantho¬ spermum hispidum plant of claim 1. 21. A method for remedying radiation sickness characterized by administering to a patient in need of such treatment a radiation sickness remedying amount of extract of the Acanthospermum hispidum plant of claim 1. 22. A method for the prophylaxis and therapy of virus diseases in mammals characterized by administering to a patient in need of such treatment an antiviral amount of extract of the Acanthospermum hispidum plant of claim 1. 23. A method for the prophylaxis and therapy of retrovirus diseases in mammals characterized by administering to a patient in need of such treatment an antiretroviral amount of extract of the Acanthospermum hispidum plant of claim 1.

Inventors: EICHMANN KLAUS, MODOLELL MANUEL, EICHMANN, KLAUS, MODOLELL, MANUEL
Applicants: MAX PLANCK GESELLSCHAFT, MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSC
Application year: 1990
Main classification: A61K35
IPC codes: A61K36, A61P31, A61P35, A61P37, B01D11, C07G99